IGMS IGM Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IGMS

Price (delayed)

$11.18

Market cap

$659.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.28

Enterprise value

$621.31M

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing ...

Highlights
IGM Biosciences's gross profit has increased by 32% YoY
IGMS's revenue is up by 32% year-on-year
The company's net income rose by 3.9% QoQ but it fell by 3.7% YoY
IGM Biosciences's equity has decreased by 33% YoY and by 21% from the previous quarter
IGM Biosciences's quick ratio has decreased by 10% YoY and by 2.6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://igmbio.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of IGMS
Market
Shares outstanding
59.02M
Market cap
$659.88M
Enterprise value
$621.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.08
Price to sales (P/S)
319.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
295.16
Earnings
Revenue
$2.11M
EBIT
-$236.33M
EBITDA
-$222.04M
Free cash flow
-$194.58M
Per share
EPS
-$4.28
Free cash flow per share
-$3.24
Book value per share
$2.74
Revenue per share
$0.04
TBVPS
$6.26
Balance sheet
Total assets
$376.13M
Total liabilities
$214.88M
Debt
$40.93M
Equity
$161.25M
Working capital
$264.82M
Liquidity
Debt to equity
0.25
Current ratio
7.98
Quick ratio
7.75
Net debt/EBITDA
0.17
Margins
EBITDA margin
-10,548%
Gross margin
100%
Net margin
-11,255.2%
Operating margin
-12,063.8%
Efficiency
Return on assets
-54%
Return on equity
-108.1%
Return on invested capital
-76.8%
Return on capital employed
-69.9%
Return on sales
-11,227.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IGMS stock price

How has the IGM Biosciences stock price performed over time
Intraday
-7.6%
1 week
4.1%
1 month
67.12%
1 year
8.33%
YTD
34.54%
QTD
62.74%

Financial performance

How have IGM Biosciences's revenue and profit performed over time
Revenue
$2.11M
Gross profit
$2.11M
Operating income
-$253.94M
Net income
-$236.92M
Gross margin
100%
Net margin
-11,255.2%
IGM Biosciences's gross profit has increased by 32% YoY
IGMS's revenue is up by 32% year-on-year
IGM Biosciences's net margin has increased by 22% YoY and by 2.7% from the previous quarter
IGMS's operating margin is up by 20% year-on-year and by 2.5% since the previous quarter

Growth

What is IGM Biosciences's growth rate over time

Valuation

What is IGM Biosciences stock price valuation
P/E
N/A
P/B
4.08
P/S
319.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
295.16
The EPS is up by 17% year-on-year and by 9% since the previous quarter
The stock's P/B is 92% above its last 4 quarters average of 2.3 but 12% below its 5-year quarterly average of 5.0
IGM Biosciences's equity has decreased by 33% YoY and by 21% from the previous quarter
IGMS's price to sales (P/S) is 39% more than its last 4 quarters average of 249.3
IGMS's revenue is up by 32% year-on-year

Efficiency

How efficient is IGM Biosciences business performance
IGMS's return on equity is down by 45% year-on-year and by 4.7% since the previous quarter
The ROA has contracted by 24% YoY
The return on sales is up by 22% year-on-year and by 2.7% since the previous quarter
The return on invested capital has declined by 18% year-on-year but it rose by 2.2% since the previous quarter

Dividends

What is IGMS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IGMS.

Financial health

How did IGM Biosciences financials performed over time
The total assets is 75% greater than the total liabilities
The total assets has declined by 19% year-on-year and by 11% since the previous quarter
IGM Biosciences's current ratio has decreased by 10% YoY and by 2.4% QoQ
IGM Biosciences's debt is 75% less than its equity
IGMS's debt to equity is up by 47% YoY and by 25% QoQ
IGM Biosciences's equity has decreased by 33% YoY and by 21% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.